Merck (MRK) EPS (Weighted Average and Diluted) (2009 - 2026)

Merck (MRK) has 18 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.72 in Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.72, down 185.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.56 (down 48.18% YoY), and the FY2025 annual result was $7.28, up 8.01% from the prior year.
• EPS (Weighted Average and Diluted) declined to -$1.72 in Q1 2026 per MRK's latest filing, from $1.2 in the prior quarter.
• Over five years, EPS (Weighted Average and Diluted) peaked at $2.32 in Q3 2025 and troughed at -$2.35 in Q2 2023.
• A 5-year average of $1.07 and a median of $1.48 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
• The sharpest annual moves came in 2023 and 2024: EPS (Weighted Average and Diluted) plunged 251.61% in 2023, then soared 408.33% in 2024.
• A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.18 in 2022, then plunged by 140.68% to -$0.48 in 2023, then soared by 408.33% to $1.48 in 2024, then declined by 18.92% to $1.2 in 2025, then plunged by 243.33% to -$1.72 in 2026.
• Business Quant data shows MRK's EPS (Weighted Average and Diluted) at -$1.72 in Q1 2026, $1.2 in Q4 2025, and $2.32 in Q3 2025.